ARS Pharmaceuticals, Inc.
SPRY
NASDAQ·Healthcare·Biotechnology·Mkt cap $558.1M
$5.62
▼ -0.88%
P/E
-2.58
Mkt Cap
$558.1M
52-Wk Range
$4.91–$13.15
52-Week Range
$4.91 - $13.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 47.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary intranasal absorption technology for epinephrine delivery
- Novel non-injectable alternative to traditional auto-injectors
- First-mover advantage in intranasal epinephrine market segment
- Addressing unmet patient needs in anaphylaxis emergency treatment
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
FDA approval and commercial launch of Neffy nasal spray
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-37.5% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying SPRY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 13, 2026
Reported EPS of -$0.63 vs -$0.48 consensus (-31.9% surprise). Revenue of $33.7M vs $31.3M expected (+7.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-31.9%
Revenue trend · last 8Q
—
—
—
—
+1472%
-68%
+184%
+114%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.1M
$86.6M
$8.0M
$15.7M
$32.5M
$28.1M
$22.7M
$33.7M
Margins · last 8Q
Gross
0.0%
Operating
-182.6%
Profit
-185.2%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · May 28, 2026
vs Industry
How SPRY stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related